Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...

Scientists created an immunotherapy that tracks pancreatic cancer even after it spreads. The breakthrough treatment works in ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

A tool for spotting pancreatic cancer in routine CT scans has had promising results, one example of how China is racing to ...

The FDA and European Medicines Agency (EMA) have awarded orphan drug designation to CPI-008 (cRGD-ZW800-1), a novel ...

The Krainer lab discovered a three-oncogene circuit that helps drive the aggressive progression of pancreatic ductal ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

A new study explains how pancreatic tumors use a sugar coating to hide from the immune system and shows that a newly ...

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with ...

BullFrog AI's bfLEAP platform identified biomarkers linked to improved survival in pancreatic adenocarcinoma patients treated with glufosfamide. The study revealed four patient clusters, with one ...